Navigation Links
Breast cancer drug shows promise against serious infections
Date:7/20/2009

An FDA-approved drug used for preventing recurrence of breast cancer shows promise in fighting life-threatening fungal infections common in immune-compromised patients, such as infants born prematurely and patients with cancer. Some scientists suspected that tamoxifen has antifungal properties; now new research from the University of Rochester Medical Center shows that it actually kills fungus cells and stops them from causing disease.

"It's still early, but if tamoxifen, or molecules like it, turns out to be an effective treatment against serious fungal infections, it'll be a welcome addition to our arsenal," said Damian Krysan, M.D., Ph.D., author of the research recently published in the journal Antimicrobial Agents and Chemotherapy and assistant professor of Pediatrics at the University of Rochester Medical Center .

While serious fungal infections are generally isolated to patients with cancer, patients in intensive care units, patients with HIV or patients taking immune-suppression medications for chronic conditions, they are among the deadliest infections. Fungus is the third most common cause of blood stream infection in premature infants in the neonatal intensive care unit. The survival rate for children with acute lymphoblastic leukemia is about 95 percent, but if they acquire a Candida albicans fungal infection, that drops to 80 percent. Bacterial meningitis has a 5 percent risk of death, but the risk of death for C. albicans blood stream infection is 20 percent.

Tamoxifen is given to prevent breast cancer from returning. It is given orally, and often for months at a time. Scientists had known that tamoxifen has anti-fungal properties in test tubes, but it was Krysan and his team, including Melanie Wellington, M.D., Ph.D., assistant professor of Pediatrics, that found that it kills yeast in mice with Candida infections. This is a crucial step toward developing tamoxifen or structurally related molecules for use in patients. At high levels about the same as those used, experimentally, to treat brain tumors tamoxifen reduced yeast levels by 150 fold. In fact, the drug caused the fungus cells to break apart and die (lysis), and it didn't allow the surviving cells to morph into their disease-causing state.

In the past 20 years, only one new class of antifungal drugs has been introduced and they must be administered intravenously, not orally, which presents challenges in outpatient settings. The most widely used antifungal drug that can be given orally slows the growth of fungus cells but it doesn't kill them, which means that patients whose immune systems are compromised may have trouble completely fighting off the infections.

"We don't have vaccines against fungal infections and the few drugs we do have aren't always effective," Krysan said. "We've got a lot more work to do to figure out whether tamoxifen could be used in high doses or whether it could be used in combination with other treatments, but we're excited about the possibility of giving doctors another way to help these critically ill patients."


'/>"/>

Contact: Heather Hare
heather_hare@urmc.rochester.edu
585-273-2840
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. MRI finds breast cancer before it becomes dangerous
3. Pathway links inflammation, angiogenesis and breast cancer
4. Drop in breast cancer incidence linked to hormone use, not mammograms
5. Breast cancer prevention practices vary across Canada
6. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
7. Acrylamide Wont Raise Breast Cancer Risk
8. New link between estrogen and breast cancer
9. Hypnosis Eases Pain of Breast Cancer Surgery
10. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
11. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... A recent report from the ... teacher preparation programs. The NCTQ report suggests, based on a review of GPA and ... improve teacher quality in the U.S. It argues that this higher bar should be ...
(Date:3/23/2017)... ... , ... The IoT (Internet of Things) is revolutionizing the way the world ... businesses and individual consumers alike. Laboratories can maximize their profit margin by increasing ... $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects the IoT ...
(Date:3/23/2017)... ... March 23, 2017 , ... Benefits ... an innovative mobile app and centralized benefits dashboard solving one of the top ... from multiple locations. For the first time, employees can access up-to-date information and ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... businesses of the greater Fort Collins area, has unveiled a collaboration with nonprofit ... involvement program. Donations to this worthy cause may now be made at ...
(Date:3/23/2017)... ... March 23, 2017 , ... ChenMed, a privately owned ... of the strategic executive team expansion needed to further optimize growth and performance. ... team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. “George Wheeler and ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... FRANCISCO , March 23, 2017  The ... interoperable system to identify and track prescription drugs as ... , in response to requirements from US FDA ... removal of potentially dangerous medicines. Blockchain ... with cryptographic identity chips and blockchain technology and recently ...
(Date:3/23/2017)... York , March 23, 2017 ... a consolidated vendor landscape with the top five ... market in 2015. These companies are Stryker Sustainability ... Hygia Health Services, Inc., and VANGUARD AG. Despite ... medical devices market is witnessing the prevalence of ...
(Date:3/23/2017)... CAMBRIDGE, Mass. , March 23, 2017 ... the enrollment of its first patient in a Phase ... an antibody-directed nanotherapeutic (ADN) that encapsulates a novel taxane ... suggest is overexpressed in 50-100% of many major tumor ... cancers. "The initiation of this study is ...
Breaking Medicine Technology: